The Oncoteq pipeline currently comprises three assets focusing on oncology. Oncoteq Asset Asset TEQ101 Target Target MetAP2 inhibition Indication Indication Renal cell carcinoma Preclinical Phase 1 Phase 2 Phase 3 Asset Asset TEQ102 Target Target CD30 Indication Indication CD30+ Lymphomas Preclinical Phase 1 Phase 2 Phase 3 Asset Asset TEQ103 Target Target ER alpha Indication Indication Breast cancer Preclinical Phase 1 Phase 2 Phase 3